Keywords
Weight loss
Complications
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Analyze systemic impacts of off-label use of semaglutide. Literature review: Semaglutide, a GLP-1 analog, was initially approved for the treatment of type 2 diabetes. Studies show that, in addition to lowering glucose levels, it promotes weight loss by inducing satiety and delaying gastric emptying, factors that reduce caloric intake. However, off-label use for weight loss, without medical supervision, is a growing practice driven by the drug’s rapid weight-loss effect and popularity. The most common adverse effects include nausea, vomiting, and risk of cholelithiasis. Aesthetic complications, such as “Ozempic Face,” characterized by facial sagging and aging, have also been reported. Final considerations: Although semaglutide shows effectiveness in weight loss, the lack of medical supervision in off-label use may lead to health risks and undesirable effects. Therefore, due to these risks, patients should be monitored, and lifestyle changes should be integrated into treatment to prevent weight regain. The popularity of off-label use highlights the need for further studies to better understand the long-term effects and to develop guidelines that ensure safe and effective use of this medication.
References
ARODA VR, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab, 2023; 25(5): 1385-1397.
BARTEL S, et al. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. The international journal of eating disorders, 2024; 57(2): 286–293.
BLUNDELL J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism, 2017; 19(9): 1242–1251.
BUTUCA A, et al. An assessment of semaglutide safety based on real world data: From popularity to spontaneous reporting in EudraVigilance database. Biomedicines, 2024; 12 (5): 1124.
CHAO AM, et al. Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, 2023; 33(3): 159–166.
CHRISTOU GA, et al. Semaglutide as a promising antiobesity drug. Obesity reviews: an official journal of the International Association for the Study of Obesity, 2019; 20(6): 805–815.
CORTES TM, et al. Effect of semaglutide on physical function, body composition, and biomarkers of aging in older adults with overweight and insulin resistance: Protocol for an open-labeled randomized controlled trial. JMIR research protocols, 2024; 13: 62667.
FRANCISQUELI FV, et al. Obesidade, inflamação e complicações metabólicas. Nutrire, 2015; 81-89.
GAO X, et al.Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers, 2022; 10: 3389.
GHUSN W, et al. Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. Int J Obes, 2024; 48: 662–667.
HAN SH, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: A Google Trends analysis. Aesthetic surgery journal, 2023; 44(1): 60–67.
LEXCHIN J, et al. Semaglutide: a new drug for the treatment of obesity. Drug and therapeutics bulletin, 2023; 61(12): 182–188.
LINCOFF AM, et al. Semaglutida e desfechos cardiovasculares na obesidade sem diabetes. New England Journal of medicine, 2023; 389(24): 2221–2232.
MAILHAC A, et al. Semaglutide (Ozempic®) use in Denmark 2018 through 2023 ‒ user trends and off-label prescribing for weight loss. Clinical epidemiology, 2024; 16: 307–318.
O’NEILL ES, et al. Injectable weight loss medications in plastic surgery: What we know, perioperative considerations, and recommendations for the future. Plastic and reconstructive surgery. Global open, 2024; 12(1): 5516.
ROCHA RI, et al. Skin changes due to massive weight loss: Histological changes and the causes of the limited results of contouring surgeries. Springer, 2021; 10:1007.
RYAN DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine, 2024; 30(7): 2049–2057.
SILLASSEN CDB, et al. Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis. BMJ open, 2024; 14(6): 84190.
SMITS MM e VAN RAALTE DH. Safety of semaglutide. Frontiers in endocrinology, 2021; 12: 645563.
SURAN M. As Ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. American Medical Association, 2023.
TAN HC, et al. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: A systematic review and meta-analysis. Journal of the ASEAN Federation of Endocrine Societies, 2022; 10: 15605.
TIMO, et al. Uso de semaglutina no tratamento da obesidade. Brazilian Journal of Health Review, 2022; 5(3): 10430–10440.
WHARTON S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab, 2022; (1): 94-105.
WILDING JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 2022; 24(8): 1553–1564.
WRIGHT JR e ARODA VR. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine, 2020; 132(2): 26-36.